

Curriculum Vitae

ERICK H. ALAYO, M.D.
alayo.erick@gastrosb.com

Education

Master in Management of Social Programs and Projects	2001
Specialization in Statistics for Research	2001
Medical Doctor	2000

Cayetano Heredia University, Lima, Peru

Residency Training

Internal Medicine Internship-Residency 2003 – 2006	
<i>John Stroger Jr. Hospital of Cook County, Chicago, Illinois</i>	
Board Certified in Internal Medicine 2006 – 2016	
Gastroenterology Fellowship – ERCP/ EUS training	2006 – 2009
<i>John Stroger Jr. Hospital of Cook County, Chicago, Illinois</i>	
Board Certified in Gastroenterology	2009 – 2022
Endobariatrics – Gastric Balloon/Weight Loss Management/Ovestitch	2018 - present

Hospital Affiliations

Scripps Mercy Hospital- Chula Vista.	2009-present
Sharp Chula Vista Medical Center.	2009-present

Clinical and Research Experience

Principal Investigator: Protocol 02-GI-002: Evaluation of ctDNA LUNAR-2 Assay in an Average Patient Screening Episode (ECLIPSE)

Principal Investigator: Protocol GB004-2101: A Phase 2, randomized, double-blind, placebo-controlled, multi-center study to evaluate GB0004 in adult subjects with mild-to-moderate active ulcerative colitis.

Sub Investigator: Allergan 3151-201-008/UC. Protocol Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis

Sub Investigator: Allergan 3151-202-008/UC. Protocol Title: A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis

Sub Investigator: Allergan 3150-301-008/CD. Protocol Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn's Disease.

Sub Investigator: Theravance 0157/UC. Study Title: A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473 in Subjects with Moderately-to-Severely Active Ulcerative Colitis

Sub Investigator: Phantom/ H-Pylori. Study Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection

Sub Investigator: Phantom/ EE Study Title: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis

Sub Investigator: MCB-103-303: IRONWOOD Pharmaceuticals-A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation. 1/09

Sub Investigator: MCB-103-305: IRONWOOD Pharmaceuticals- An Open-label, Long-term Safety Study of Oral Linaclotide Administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. 1/09

Sub Investigator: SPD476-313 SHIRE PHARMACEUTICALS-A Phase III, Randomized, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis

Sub Investigator: MCP-103-302: IRONWOOD Pharmaceuticals-A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation with Irritable Bowel Syndrome. 9/2009

Sub Investigator: ASMP3001 :TIOGA Pharmaceuticals, Inc. A 12-Week Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). 9/2010

Sub Investigator: PA32540-301 :POZEN Pharmaceuticals .A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers April 2010

Sub Investigator: BUCF3002: SALIX Pharmaceuticals: A Phase 3, Randomized, double blind placebo controlled multicenter study to assess the efficacy and safety of budesonide foam (2mg/25ml bid for 2 weeks, followed by 2mg/25 ml qd for 4 weeks) versus placebo in subjects with active mild to moderate ulcerative proctitis or proctosigmoiditis

Sub Investigator - Eisai, Protocol E3810-G001-301,303, A Randomized Double-Blind Parallel Study of Rabeprazole ER 50 mg versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Erosive Gastroesophageal Reflux Disease (GERD). 2009

Sub Investigator - E810-G000-305: EISAI Pharmaceuticals-A Randomized Double-Blind parallel study and of Rabeprazole Extended release 50mg versus Esomeprazole 40 mg for maintenance of erosive gastroesophageal reflux disease (GERD). 2009

Sub Investigator - MCP-103-305: IRONWOOD Pharmaceuticals- An Open-label, Long-term Safety Study of Oral Linaclotide Administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. 2009

Sub Investigator - SPD476-313 A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis. 2009

Clinical and Research Experience – continued

Sub Investigator - MCP-103-302: IRONWOOD Pharmaceuticals_A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation. 2009

Research Physician 2000 – 2002

AB PRISMA, Lima, Peru

- “Epidemiology of *Helicobacter pylori* infection in Lima.”
- “*Helicobacter pylori* infection in Peruvian patients and in patients of Japanese ascendance residents in Peru.”
- “Latent pulmonary tuberculosis in autopsied humans: Molecular, bacteriologic and pathologic studies.”

Research Physician 2000 – 2002

Alexander von Humbolt Institute of Tropical Medicine, Lima, Peru

- “The Influence of the El Niño phenomenon on the epidemiology of Vector transmitted diseases.”

Consultant – Medicine and Odontology (undergraduate & graduate theses) 1998 – 2002

Cayetano Heredia University (UPCH), Lima Peru

Physician - Rural Service 2000 – 2001

Peruvian Ministry of Health, Lima, Peru

Physician 2000 – 2001

“San Jose” Clinical Center, Lima, Peru

Co-Investigator – Gastrointestinal Physiology Working Group 1997 – 2000

Cayetano Heredia and Johns Hopkins Universities, Lima, Peru

Co-Investigator – Endocrinology Laboratory 1997 – 2000

Cayetano Heredia University, Lima, Peru

Co-Investigator – Ophthalmology 1997 – 1999

Arzobispo Loayza Hospital, Lima, Peru

Teaching Experience

Teacher of Physiopathology	2000 – 2001
Teacher of Medical English	2000 – 2001
Teacher of Microbiology and Histology	1998 – 2000
Medical Technology School, Faculty of Medicine “Alberto Hurtado” <i>Cayetano Heredia University (UPCH), Lima, Peru</i>	

Editorial Assignments

Reviewer

<i>Critical Care Medicine</i> ♦ <i>Emerging Infectious Diseases</i> ♦ <i>CHEST</i> <i>American Journal of Tropical Medicine and Hygiene</i> ♦ <i>British Medical Journal</i> <i>Gastroenterology</i> ♦ <i>Clinical Gastroenterology and Hepatology</i>	2003 – present
--	----------------

Awards and Scholarships

- *First Prize, National Research Project Convocation, CONCYTEC, 2002*
- *National Award in Investigation in Medicine ABEEFE Bristol-Myers, 2001*
- *Scholarship, “School of Public Health-UPCH,” Master in Management of Social Programs and Projects, 2000-2001*
- *Scholarship, “Statistics Department-UPCH,” Specialization in Statistics for Research, 2000-2001*
- *National Award in Investigation in Pediatrics HERSIL, 2000*
- *National Award AVENTIS for the Best Article Published in a Peruvian Journal, 2000*

Awards and Scholarships

- *Second Prize for the Best Presentation, National Congress of Internal Medicine, 2000*
- *First Prize for the Best National Research in Health Sciences, “HIPÓLITO UNANUE,” 2000*
- *National Award in Investigation in Medicine ABEEFE Bristol-Myers, 1999*

- "Honor to Success" Award, Procter & Gamble, 1998
- Second Prize, National Competition of Ophthalmologic Research, 1998

Grants

- "Variation in the *H. pylori* prevalence and its relation with the chloride levels in water of Lima, Peru," (1985 to 2002), funded by CONCYTEC-Peru, 2002
- *The Influence of the El Niño phenomenon on the epidemiology of Bartonellosis in the Peruvian Department of Ancash*," funded by CONCYTEC-Peru, 2001
- "Prevalence of Lactose Intolerance in Peruvian Children," funded by The Child Health Institute of North America, 1999

Publications

Alayo E, Attar B, Go B. A Case of Recurrent Abdominal Pain Due to a Gossypiboma With Spontaneous Resolution. *Clin Gastroenterol Hepatol.* 2009 Sep 3

Ramírez-Ramos A, Watanabe-Yamamoto J, Takano-Morón J, Gilman RH, Recavarren Arce S, Arias-Stella J, Yoshiwara-Wakabayashi E, Rodríguez-Ulloa C, Miyagui-Maeda J, **Alayo E**, et al. Decrease in prevalence of peptic ulcer and gastric adenocarcinoma at the Policlínico Peruano Japonés, Lima, Peru, between the years 1985 and 2002. Analysis of 31,446 patients. *Acta Gastroenterol Latinoam.* 2006 ;36:139-46.

Ramírez-Ramos A, Gilman RH, Watanabe-Yamamoto J, Takano-Moron J, Arias-Stella J, Yoshiwara-Wakabayashi E, Rodríguez-Ulloa C, Miyagui-Maeda J, Velapatiño-Cochachi B, Mendoza-Requena D, **Alayo E**, et al. Comparison of the prevalence of *Helicobacter pylori* stomach infection in Peruvian and Japanese population. *Acta Gastroenterol Latinoam.* 2005;35:219-24.

León-Barúa R, Recavarren S, **Alayo E**, Gilman R. *Helicobacter pylori*-associated chronic atrophic gastritis probably predisposing to severely dehydrating diarrheal disease by *Vibrio Cholera*. *Trans R Soc Trop Med Hyg.* 2006;100:567-72.

Alayo E, Villena J, Evans A, Zimic M. Can hormones levels improve the ability to predict intensive care unit mortality? *Intensive Care Medicine* July 2005.

Publications – continued

- Recavarren S, Ramirez Ramos A, Gilman R, **Alayo E**. Severe *Helicobacter pylori*-associated gastritis in the Peruvian Andes. *Histopathology* 2005;46, 374-379.
- Alayo E**, Huarcaya E, Nasarre C, del Aguila R, Llanos A. The Influence of the El Niño phenomenon on the epidemiology of Bartonellosis in the Peruvian department of Ancash. *Trans R Soc Trop Med Hyg.* 2004;98:116-124.
- Ramírez Ramos A, **Alayo E**, Mendoza D, Leey J, Segovia M, Otoyá C. Changes in the prevalence of *H. pylori* in Peru; 1985-2002 period in medium and upper socio-economic strata (translated from Spanish version). *Rev Gastroenterol Peru.* 2003;23(2):92-8.
- Rodríguez W, Watanabe-Yamamoto J, Ramírez Ramos A, Gilman HR, Rodríguez Ulloa C, Pareja Cruz A, Yushimito L, **Alayo E**, et al. Omeprazole, amoxicillin and clarithromycin in the treatment of *helicobacterpylori*, in 7 and 10-day regimens (translated from Spanish version). *Rev Gastroenterol Peru.* 2003 Jul-Sep;23(3):177-83.
- Peinado J, **Alayo E**, Mendoza D, Rosas A, Nasarre C, Llanos F. Use of Geographic Information Systems to evaluate the association of asthmatic crisis in children living within factory-contaminated areas in the district of San Martín de Porres. 1997-1998 (translated from Spanish version). *Rev Peru Med Exp Salud Publica* 2002; 19(3): 124-130.
- Luy G, Maldonado G, **Alayo E**, Peinado J, Luy V. Clinical characteristics of colonic cancer. E. Rebagliati Martins Hospital, 1995-1999 (translated from Spanish version). *Rev Gastroenterol Peru.* 2001; 20:4: 406-413.
- Cubillas R, Maguiña C, Saona P, **Alayo E**, Llanos E: Prevalence of Anti-Toxoplasma Gondii antibodies in pregnant women at the Cayetano Heredia National Hospital – February 1998 (translated from Spanish version). *Boletín de la Sociedad Peruana de Medicina Interna.* 2000;13(4):124.
- Ramírez-Ramos A, Recavarren S, Arias Stella J, León-Barúa R, Gilman R, Watanabe E, **Alayo E**. *Helicobacter pylori*, chronic gastritis, gastric ulcer and duodenal ulcer: study in 1638 patients (translated from Spanish version). *Rev Gastroenterol Peru.* 1999; 19(3):196.
- Ramírez-Ramos A, Gilman R, Recavarren S, León-Barúa R, Watanabe E, Arias Stella J, **Alayo E**. Contribution to the study of the epidemiology of *Helicobacter pylori* in Peru: analysis of 3005 cases (translated from Spanish version). *Rev Gastroenterol Peru.* 1999; 19(3):190.
- Alzamora B, Tobaru L, Haro D, Chavez R, **Alayo E**. Clinical trial using Clotrimazol 1%, systemic Ketoconazol and sytemic Fluconazol in the treatment of mycotic keratitis (translated from Spanish version). *Revista Peruana de Oftalmología.* 1999;23(1):37.

Alayo E, Chavez J, Namisato C, Larco J, Reyes C, Leon Barua R, Sack B, Salazar E. Prevalence of lactose intolerance in Peruvian children and adults. *In preparation*.

Nasarre C, Mendoza C, **Alayo E**, Chumpitaz RM, Cabero D, Fuentes P, Gilman RH. Latent pulmonary tuberculosis in autopsied humans: molecular, bacteriologic and pathologic studies. *In preparation*.

Ramírez-Ramos A, Gilman HR, Watanabe-Yamamoto J, Takano-Moron J, Arias-Stella J, Yoshiwara Wakabayashi E, Rodríguez-Ulloa C, Miyagui Maeda J, Velapatino Cochachi B, Mendoza-Requena D, **Alayo E**, et al. Helicobacter pylori infection in a Japanese population in Lima, Peru. *In preparation*.

Thesis

Mortality predictive value of the index Cortisol/ Triiodothyronine on the admission to the General Intensive Care Unit. *Thesis of Medicine - Cayetano Heredia University. 1998*.

Book

Ramirez Ramos A and **Alayo E**. Gastrointestinal alterations in the elderly (translated from Spanish version). *Gerontology Topics. Varela, L 2nd Ed. UPCH, Lima. 2002;pp:200*.

Abstracts and Presentations

Alayo E, Attar B, Abrahamian F. Cholestatic Hepatitis Associated with Hyperthyroidism, and Exacerbated by Methimazole Therapy. *American College of Gastroenterology Annual Meeting 2007. Philadelphia, PA*.

Smith CA, **Alayo E**, Fung S, Evans AT, Reilly BM, Mandelbaum S. Use of a Screening Tool by Medical Residents to Recognize and Treat Major Depression in Hospitalized Patients: A Controlled Trial. *SGIM Annual Meeting, Los Angeles, 2006*.

Alayo E, Smith CA, Mandelbaum S, Fung S, Evans AT. The test characteristics of a new depression Tool used by Medicine Residents evaluating Hospital Admissions. *SGIM Annual Meeting, Los Angeles, 2006*.

Attar BM, Halliburton C, **Alayo E**. Correlation of ultrasonography and histology in patients with steatosis. *Gastroenterology. 2006;130:A-595*.

Attar BM, Guthrie G, **Alayo E**, Orucevic A. Are Hispanics at increased risk for NASH? *Digestive Disease Week 2005, Chicago, IL*.

Attar BM, Evans AT, Pandolfi G, Vladic F, **Alayo E**, Orucevic A, Reilly BM. Diabetes mellitus versus HIV co-infection: Which one leads to more fibrosis in HCV patients? *Digestive Disease Week 2005, Chicago, IL.*

Shi F, Ferrer K, Attar BM, **Alayo E**, Pandolfi G, Sekosan M, Orucevic A. Histopathology of the liver in untreated human immunodeficiency virus and hepatitis C (HIV/HCV) coinfecting patients in a county hospital. *US and Canadian Academy of Pathology Annual Meeting. 2005.*

Attar BM, Vladic F, Pandolfi G, **Alayo E**, Orucevic A. The impact of Diabetes Mellitus and Steatosis on Hepatic Fibrosis and Inflammation in HCV Patients. *Annual Meeting of the American Society for the Study of Liver Diseases. 2004. Boston, MA.*

Attar BM, Pandolfi G, Vladic F, **Alayo E**, Adeyemi O, Cotler S, Jensen D. Race as an important factor on the model construction for predicting HCV-related fibrosis. *American College of Gastroenterology Annual Meeting 2004. Orlando, LA.*

Attar BM, **Alayo E**, Pandolfi G, Adeyemi O, Cotler S, Jensen D. Factors implicated in receiving therapy in patients with Hepatitis C ± HIV co-infection in a lower socioeconomic group. *American College of Gastroenterology Annual Meeting 2004. New Orleans, LA.*

Abstracts and Presentations

Attar BM, Pandolfi G, Vladic F, **Alayo E**, Orucevic A, Atten M. Prediction of HCV-related fibrosis and inflammation based on a constructed model. *Digestive Disease Week 2004. New Orleans, LA.*

León-Barúa R, Recavarren S, **Alayo E**, Gilman R. Helicobacter pylori-associated chronic atrophic gastritis probably predisposing to severely dehydrating diarrheal disease by Vibrio Cholera. *Annual Meeting of the American Society of Tropical Medicine and Hygiene. 2002. Denver, Colorado.*

Ventosilla P, Huarcaya E, **Alayo E**, León F, Palacios A, Gutierrez P, Vidal S, Aron J. Influence of El Niño event on the transmission of malaria in Luciano Castillo & Colonna (Piura, Perú). *Conference in Climate Variability and Change and Their Health Effects in the Caribbean. 2002. Barbados.*

Alayo E, Huarcaya E, Peinado J, Llanos A. The Influence of the El Niño phenomenon on the epidemiology of Bartonellosis in the Peruvian Department of Ancash. *Annual Meeting of the American Society of Tropical Medicine and Hygiene. 2001. Atlanta, Georgia.*

Alayo E, Villena J, Contardo M. Mortality Predictive value of the index Cortisol / Triiodothyronine on the admission to the General Intensive Care Unit. *National Congress of Internal Medicine. 2000. Peru.*

Alayo E, Villena J, Contardo M. Thyroid function in patients in the General Intensive Care Unit and its relation to mortality. *International Scientific Medical Student Congress XIV - FELSOCEM. 1999. Panama.*

Academic Affiliations / Activities

- *Medical Intern Representative*, UPCH, 1999-2000
- *Member*, Scientific Society of Medical Students, UPCH, 1999-2000
- *Student Representative*, University Assembly, UPCH, 1998-2000
- *Founding Member*, Medical Student Association, UPCH, 1998-2000
- *Student Representative*, Council of the Faculty of Medicine, UPCH, 1997-1998

Disclosures

- *Speaker for Ironwood Pharmaceuticals, 2016.*
- *Speaker for Salix Pharmaceuticals, Since 2019.*
- *Speaker for Boston Scientific, Since 2019.*
- *Advisor for Pfizer Pharmaceuticals, Since 2019.*
- *Speaker for Redhill Biopharma, Since 2020.*

Other skills

- *Bilingual in Spanish and English.*
- *Software skills include database and statistical packages, such as EPI INFO 6.04, SPSS 10.0, MAPINFO 4.12, and STATA v.8.0.*